Clinical Decision-Making for Drug-Resistant Tuberculosis

Drug-resistant tuberculosis (DR-TB) is an important challenge for clinicians. With the introduction of rapid molecular diagnostic tests, the notification of DR-TB is increasing and the time to diagnosis can be shortened, allowing earlier treatment initiation. Shorter treatment regimens (STR) have been recommended by WHO since 2016, thus simplifying treatment for patients and National TB Programs alike. Access to bedaquiline, pretomanid, delamanid, linezolid, and clofazimine is increasing and guidelines are adapted frequently. Clinicians require training in the use of these new diagnostic tools, the interpretation of guidelines, and in making informed choices for treatment initiation and monitoring and in adequate and timely clinical decision making, also for the most resistant forms of TB.

For this course, we have a partnership with: Damien Foundation, MSF and Nottingham Trent University.

This blended course offers interdisciplinary and interactive training on clinical aspects of DR TB diagnosis and care. It consists of a 10-week online training, followed by 2 weeks face-to-face (includes 1 public holiday).